Lesley-Ann Martin

9PUBLICATIONS
69CO-AUTHORS
Cancer geneticsPredictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Econometric and statistical methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Sep 02, 2025
Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.

Eric Hahnen, Jan Hauke, Karen Gelmon

|Apr 10, 2025
BRCA1/2 and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2- Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis.

Eric Hahnen, Jan Hauke, Karen Gelmon

|Oct 02, 2024
Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast Cancer.

Carolina Gemma, Chun-Fui Lai, Anup K Singh

|Oct 06, 2023
Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers.

Arany Soosainathan, Marjan Iravani, Rania El-Botty

|Nov 29, 2022
Elacestrant demonstrates strong anti-estrogenic activity in PDX models of estrogen-receptor positive endocrine-resistant and fulvestrant-resistant breast cancer.

Sunil Pancholi, Nikiana Simigdala, Ricardo Ribas

|Dec 06, 2019
Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer.

Sunil Pancholi, Mariana Ferreira Leal, Ricardo Ribas

Pageof 2

Frequent Collaborators

2 joint publications

Frederik Marmé

2 joint publications

Angela DeMichele

2 joint publications

Michael Untch

2 joint publications

Erik Knudsen